CHRYSALIS-2 is an open-label study, which includes a single-arm cohort (cohort A) examining patients with EGFR Exon19del or NSCLC L858R whose disease progressed after platinum chemotherapy and in previously treated patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.